MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations

Journal of Molecular and Cellular Cardiology

Volumn 65, Issue , 2013, Pages 59-66

  Kuster, Diederik W D ^a,b   Mulders, Joyce ^c   ten Cate, Folkert J ^d   Michels, Michelle ^d   dos Remedios, Cristobal G ^e   da Costa Martins, Paula A ^f   van der Velden, Jolanda ^a,g   Oudejans, Cees B M ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF SYDNEY   (Australia)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Heart; Hypertrophic cardiomyopathy; MicroRNA; MYBPC3; Profiling; TRPM3

Indexed keywords

ANNEXIN; ANNEXIN 11; ATAXIN 1; BETA ADRENERGIC RECEPTOR; CARDIAC MYOSIN BINDING PROTEIN C; CATION CHANNEL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN D1; CYCLIN D3; MICRORNA; MICRORNA 10A; MICRORNA 10B; MICRORNA 181A 2; MICRORNA 184; MICRORNA 204; MICRORNA 222; MICRORNA 34B; MICRORNA 371 3P; MICRORNA 383; MICRORNA 497; MICRORNA 708; MICRORNA 96; PANTOTHENATE KINASE; PANTOTHENATE KINASE 1; PODOCALYXIN; PROTEIN BCL 2; SORTILIN; STRUCTURAL PROTEIN; TRANSCRIPTOME; TROPONIN I; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCIUM TRANSPORT; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE MUTATION; GENOMICS; HEART MUSCLE; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; INTRON; MALE; MICROARRAY ANALYSIS; MYBPC3 GENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMERE; SIGNAL TRANSDUCTION; TRPM3 GENE; UPREGULATION;

HEART; HYPERTROPHIC CARDIOMYOPATHY; MICRORNA; MYBPC3; PROFILING; TRPM3;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; CARRIER PROTEINS; COMPUTER SIMULATION; FEMALE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUTATION; MYOCARDIUM; PHOSPHORYLATION; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TROPONIN I; TRPM CATION CHANNELS; YOUNG ADULT;

EID: 84885502197     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.09.012     Document Type: Article

References (34)

1. Gersh B.J., Maron B.J., Bonow R.O., Dearani J.A., Fifer M.A., Link M.S., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 124:2761-2796.
2. Schlossarek S., Mearini G., Carrier L. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. J Mol Cell Cardiol 2011, 50:613-620.
3. Maron B.J., Gardin J.M., Flack J.M., Gidding S.S., Kurosaki T.T., Bild D.E. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995, 92:785-789.
4. Maron B.J. Sudden death in young athletes. N Engl J Med 2003, 349:1064-1075.
5. Harris S.P., Lyons R.G., Bezold K.L. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res 2011, 108:751-764.
6. Timmer S.A., Germans T., Brouwer W.P., Lubberink M., van der Velden J., Wilde A.A., et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction. Eur J Heart Fail 2011, 13:1283-1289.
7. van Dijk S.J., Dooijes D., dos Remedios C., Michels M., Lamers J.M., Winegrad S., et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009, 119:1473-1483.
8. Page S.P., Kounas S., Syrris P., Christiansen M., Frank-Hansen R., Andersen P.S., et al. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circ Cardiovasc Genet 2012, 5:156-166.
9. Alders M., Jongbloed R., Deelen W., van den Wijngaard A., Doevendans P., Ten Cate F., et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. Eur Heart J 2003, 24:1848-1853.
10. Michels M., Soliman O.I., Kofflard M.J., Hoedemaekers Y.M., Dooijes D., Majoor-Krakauer D., et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging 2009, 2:58-64.
11. Liu N., Olson E.N. MicroRNA regulatory networks in cardiovascular development. Dev Cell 2010, 18:510-525.
12. Gladka M.M., da Costa Martins P.A., De Windt L.J. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol 2012, 52:74-82.
13. Topkara V.K., Mann D.L. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther 2011, 25:171-182.
14. Zaremba R., Merkus D., Hamdani N., Lamers J.M., Paulus W.J., Dos Remedios C., et al. Quantitative analysis of myofilament protein phosphorylation in small cardiac biopsies. Proteomics Clin Appl 2007, 1:1285-1290.
15. Ponting C.P., Oliver P.L., Reik W. Evolution and functions of long noncoding RNAs. Cell 2009, 136:629-641.
16. Courboulin A., Paulin R., Giguere N.J., Saksouk N., Perreault T., Meloche J., et al. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011, 208:535-548.
17. Lee N., Chen J., Sun L., Wu S., Gray K.R., Rich A., et al. Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J Biol Chem 2003, 278:20890-20897.
18. Grimm C., Kraft R., Sauerbruch S., Schultz G., Harteneck C. Molecular and functional characterization of the melastatin-related cation channel TRPM3. J Biol Chem 2003, 278:21493-21501.
19. Naylor J., Li J., Milligan C.J., Zeng F., Sukumar P., Hou B., et al. Pregnenolone sulphate- and cholesterol-regulated TRPM3 channels coupled to vascular smooth muscle secretion and contraction. Circ Res 2010, 106:1507-1515.
20. Majeed Y., Tumova S., Green B.L., Seymour V.A., Woods D.M., Agarwal A.K., et al. Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone. Cell Calcium 2012, 51:1-11.
21. Kunert-Keil C., Bisping F., Kruger J., Brinkmeier H. Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains. BMC Genomics 2006, 7:159.
22. Ashrafian H., McKenna W.J., Watkins H. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res 2011, 109:86-96.
23. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
24. Kuster D.W., Bawazeer A.C., Zaremba R., Goebel M., Boontje N.M., van der Velden J. Cardiac myosin binding protein C phosphorylation in cardiac disease. J Muscle Res Cell Motil 2012, 33:43-52.
25. van Dijk S.J., Paalberends E.R., Najafi A., Michels M., Sadayappan S., Carrier L., et al. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail 2012, 5:36-46.
26. Latronico M.V., Condorelli G. microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood) 2011, 236:125-131.
27. Ikeda S., He A., Kong S.W., Lu J., Bejar R., Bodyak N., et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009, 29:2193-2204.
28. Care A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
29. Callis T.E., Pandya K., Seok H.Y., Tang R.H., Tatsuguchi M., Huang Z.P., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009, 119:2772-2786.
30. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006, 103:18255-18260.
31. da Costa Martins P.A., Salic K., Gladka M.M., Armand A.S., Leptidis S., el Azzouzi H., et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010, 12:1220-1227.
32. Palacin M., Reguero J.R., Martin M., Diaz Molina B., Moris C., Alvarez V., et al. Profile of microRNAs differentially produced in hearts from patients with hypertrophic cardiomyopathy and sarcomeric mutations. Clin Chem 2011, 57:1614-1616.
33. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
34. Gaborit N., Le Bouter S., Szuts V., Varro A., Escande D., Nattel S., et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 2007, 582:675-693.